Prevailing effectiveness of the 2009 influenza A(H1N1)pdm09 vaccine during the 2010/11 season in Sweden

Eurosurveillance

Volumn 18, Issue 15, 2013, Pages

  Widgren, K ^a   Magnusson, M ^a   Hagstam, P ^b   Widerstrom M ^b   Ortqvist A ^b,c   Einemo, I M ^b   Follin, P ^b   Lindblom, A ^b   Makitalo S ^b   Wik, O ^b   Osterlund A ^b   Grunewald M ^a   Uhnoo, I ^a   Linde, A ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b Department of Communicable Disease Control and Prevention ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; INFECTION CONTROL; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SWEDEN; VACCINATION;

EID: 84876502278     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. European Centre for Disease Prevention and Control (ECDC). Seasonal Influenza 2010-2011 in Europe (EU/EEA countries). Stockholm: ECDC; 2011. Available from:http://ecdc.europa.eu/en/publications/publications/110125_ra_seasonal_influenza_eu-eea_2010-2011.pdf
2. Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines. 2010;9(12):1385-98. http://dx.doi.org/10.1586/erv.10.141. PMid:21105775.
3. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194 Suppl 2:S111-8. http://dx.doi.org/10.1086/507544. PMid:17163383.
4. World Health Organization (WHO). Influenza pandemic preparedness and response, Report by the secretariat. Geneva: WHO; 2005. Contract No.: EB115/44. Available from:http://www.wpro.who.int/emerging_diseases/documents/docs/B115_44en.pdf
5. Pandemic influenza A (H1N1) 2009 virus vaccine-conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. Wkly Epidemiol Rec. 2009;84(49):505-8. PMid:19960623.
6. Influensa A(H1N1) 2009-Utvärdering och förberedelser för hantering av pandemin. [Influenza A(H1N1) 2009-Evaluation and preparation for managament of the pandemic]. Stockholm: Socialstyrelsen, Karlstad: Myndigheten för samhällsskydd och beredskap; 2011. ISBN: 978-91-86585-84-6. Swedish. Available from:http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18243/2011-3-3.pdf
7. Cheng AC, Kotsimbos T, Kelly HA, Irving LB, Bowler SD, Brown SG, et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study. Vaccine. 2011;29(43):7320-5. http://dx.doi.org/10.1016/j.vaccine.2011.07.087. PMid:21810450.
8. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8(1):e1000388. http://dx.doi.org/10.1371/journal.pmed.1000388. PMid:21379316. PMCid:3019108.
9. Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, SebastianPillai P, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill. 2011;16(2):pii=19763. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19763
10. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, et al. Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities. PloS One. 2011;6(8):e23085. http://dx.doi.org/10.1371/journal.pone.0023085. PMid:21857999. PMCid:3155536.
11. Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I, Turbelin C, et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France. PloS One. 2011;6(5):e19621. http://dx.doi.org/10.1371/journal.pone.0019621. PMid:21573005. PMCid:3091864.
12. Steens A, Wijnans EG, Dieleman JP, Sturkenboom MC, van der Sande MA, van der Hoek W. Effectiveness of a MF-59-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study. BMC Infect Dis. 2011;11:196. http://dx.doi.org/10.1186/1471-2334-11-196. PMid:21767348. PMCid:3154871.
13. Steens A, van der Hoek W, Dijkstra F, van der Sande M. Influenza vaccine effectiveness, 2010/11. Euro Surveill. 2011;16(15):pii=19843. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19843. PMid:21507318.
14. Hardelid P, Fleming DM, Andrews N, Barley M, Durnall H, Mangtani P, et al. Effectiveness of trivalent and pandemic influenza vaccines in England and Wales 2008-2010: results from a cohort study in general practice. Vaccine. 2012;30(7):1371-8. http://dx.doi.org/10.1016/j.vaccine.2011.12.038. PMid:22178524.
15. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis. 2011;17(7):1181-7. http://dx.doi.org/10.3201/eid1707.101959. PMid:21762570. PMCid:3381383.
16. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Perez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010;28(47):7460-7. http://dx.doi.org/10.1016/j.vaccine.2010.09.042. PMid:20875486.
17. Gilca R, Deceuninck G, De Serres G, Boulianne N, Sauvageau C, Quach C, et al. Effectiveness of Pandemic H1N1 Vaccine Against Influenza-Related Hospitalization in Children. Pediatrics. 2011;128(5):e1084-91. http://dx.doi.org/10.1542/peds.2010-3492. PMid:21987710.
18. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ. 2011;342:c7297. http://dx.doi.org/10.1136/bmj.c7297. PMid:21292718. PMCid:3033439.
19. Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 2010;15(18):pii=19561. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19561. PMid:20460094.
20. Emborg HD, Krause TG, Hviid A, Simonsen J, Mølbak K. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ. 2011;344:d7901. http://dx.doi.org/10.1136/bmj.d7901. PMid:22277542.
21. Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis. 2011;203(1):32-9. http://dx.doi.org/10.1093/infdis/jiq014. PMid:21148494. PMCid:3086445.
22. Örtqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis. 2011;52(10):1203-11. http://dx.doi.org/10.1093/cid/cir182. PMid:21507917.
23. Smittskyddsinstitutet (SMI). Influensa i Sverige, säsongen 2010-2011. [Influenza in Sweden, the 2010-2011 season]. Stockholm: SMI; 2011. Swedish. Available from:http://www.smittskyddsinstitutet.se/upload/Publikationer/Influensa-i-Sverige-2010-11-artikelnr-2011-15-2.pdf
24. Läkemedelsverket. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations-Results of a case inventory study by the MPA in Sweden during 2009-2010. Stockholm: Läkemedelsverket; 2011. Available from:http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf
25. National Narcolepsy Task Force Interrim Report. Helsinki: National Institute for Health and Welfare; 2011. Available from: http://www.thl.fi/thl-client/pdfs/dce182fb-651e-48a1-b018-3f774d6d1875
26. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland. PloS One. 2012;7(3):e33536. http://dx.doi.org/10.1371/journal.pone.0033536. PMid:22470453. PMCid:3314666.
27. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland. PloS One. 2012;7(3):e33723. http://dx.doi.org/10.1371/journal.pone.0033723. PMid:22470463. PMCid:3314680.
28. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010-Final Report of National Narcolepsy Study Steering Committee. Dublin: Irish Department of Health; 2012. Available from: http://healthupdate.gov.ie/wp-content/uploads/2012/04/Final_Report_of_National_Narcolepsy_Study_Steering_Committee-latest1.pdf
29. Folkehelseinstituttet (FHI). Rapport om utredning av narkolepsi etter Pandemrix [Report from the investigation of narcolepsy after Pandemrix]. Oslo: FHI; 2011. Norwegian. Available from: http://www.fhi.no/dav/842b470e7d.pdf
30. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63(6):1055-68. PMid:3879673. PMCid:2536484.
31. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742-6. http://dx.doi.org/10.1093/ije/22.4.742. PMid:8225751.
32. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008(2):CD004879. PMid:18425905.
33. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(33):1128-32. PMid:21866086.
34. Granström M, Voordouw AC. Registration of influenza vaccines for children in Europe. Vaccine. 2011;29(43):7572-5. http://dx.doi.org/10.1016/j.vaccine.2011.08.017. PMid:21820474.
35. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. 2010;340:c2649. http://dx.doi.org/10.1136/bmj.c2649. PMid:20508026. PMCid:2877808.
36. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365(15):1406-16. http://dx.doi.org/10.1056/NEJMoa1010331. PMid:21995388.
37. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28(7):563-71. http://dx.doi.org/10.1097/INF.0b013e31819d6394. PMid:19561422.
38. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 2012;205(5):733-44. http://dx.doi.org/10.1093/infdis/jir641. PMid:22315336.
39. Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, et al. H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. Clin Infect Dis. 2012;54(5):661-9. http://dx.doi.org/10.1093/cid/cir905. PMid:22267719. PMCid:3275760.
40. Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine. 2011;30(1):35-41. http://dx.doi.org/10.1016/j.vaccine.2011.10.062. PMid:22063386.
41. Mörner A, Bråve A, Kling AM, Kühlmann-Berenzon S, Krook K, Hedenskog M, et al. Pandemic Influenza A(H1N1)pdm09 Seroprevalence in Sweden before and after the Pandemic and the Vaccination Campaign in 2009. PloS One. 2012;7(12):e53511. http://dx.doi.org/10.1371/journal.pone.0053511. PMid:23285299 PMCid:3532299.
42. European Medicines Agency (EMA). European Medicines Agency recommends restricting use of Pandemrix. Press release. London: EMA; 2011. [Accessed 19 Apr 2012]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000034.jsp&mid=WC0b01ac058001d126&jsenabled=true#press-release
43. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PloS One. 2011;6(11):e27622. http://dx.doi.org/10.1371/journal.pone.0027622. PMid:22110695 PMCid:3216983.
44. Pebody RG, Andrews N, Fleming DM, McMenamin J, Cottrell S, Smyth B, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect. 2012;13:1-11.
45. Castilla J, Moran J, Martinez-Artola V, Reina G, Martinez-Baz I, Garcia Cenoz M, et al. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill. 2011;16(7):pii=19799. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19799. PMid:21345321.
46. Savulescu C, Jiménez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill. 2011;16(11):pii=19820. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19820. PMid:21435330.
47. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis. 2012;55(3):332-42. http://dx.doi.org/10.1093/cid/cis431. PMid:22539661.
48. Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine. 2012;30(24):3595-602. http://dx.doi.org/10.1016/j.vaccine.2012.03.048. PMid:22472792.
49. Valenciano M, Ciancio B, Moren A, the influenza vaccine effectiveness working group. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. Euro Surveill. 2008;13(43):pii=19015. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19015. PMid:18947520.
50. Kroneman MW, van Essen GA. Variations in influenza vaccination coverage among the high-risk population in Sweden in 2003/4 and 2004/5: a population survey. BMC Public Health. 2007;7:113. http://dx.doi.org/10.1186/1471-2458-7-113. PMid:17570837. PMCid:1906854.
51. Athanasiou M, Baka A, Andreopoulou A, Spala G, Karageorgou K, Kostopoulos L, et al. Influenza surveillance during the post-pandemic influenza 2010/11 season in Greece, 04 October 2010 to 22 May 2011. Euro Surveill. 2011;16(44):pii=20004. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20004
52. Health Protection Agency (HPA). Surveillance of influenza and other respiratory viruses in the UK, 2010/11. London: HPA; 2011. Available from:http://www.hpa.org.uk/Publications/InfectiousDiseases/Influenza/1105influenzareport/
53. Glismann SO, Knudsen LK, Gubbels S, Mølbak K, Bragstad K, Nielsen LP. Influenza season 2010/2011. EpiNews. 2011;23. Available from: http://www.ssi.dk/English/News/EPI-NEWS/2011/No%2023%20-%202011.aspx
54. Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, et al. A New Sentinel Surveillance System for Severe Influenza in England Shows a Shift in Age Distribution of Hospitalised Cases in the Post-Pandemic Period. PloS One. 2012;7(1):e30279. http://dx.doi.org/10.1371/journal.pone.0030279. PMid:22291929. PMCid:3264602.